Abstract: The present disclosure is directed to devices and methods for synchronizing capturing of spectral images, capturing of thermal images, and capturing of panchromatic images. A thermal imaging device of an aerial vehicle captures a sequence of thermal images. Capturing of spectral images by a spectral imaging device of the aerial vehicle is synchronized with the capturing of the thermal images. Capturing of panchromatic images is synchronized with the capturing of thermal images. Irradiance data indicative of a background temperature is sensed. A digital surface model of an area of interest is generated based on the sequence of spectral images. An emissivity of a target is estimated and a temperature of a pixel of the digital surface model of the target is estimated based on the sequence of thermal images, the irradiance data indicative of the background temperature and the estimated emissivity of the target.

Abstract: The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors.

Abstract: Described herein are systems relating to a continuous-flow instrument that includes all necessary components for digital droplet quantification without the need to introduce key reagents or collect and transfer droplets between stages of instrument operation. Digital quantification can proceed without any additional fluid or consumable handling and without exposing fluids to risk of external contamination.

Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof wherein A, E, U, X, Y, Z, R1, R2 and n are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases. Also provided herein are pharmaceutical compositions comprising the compounds of the invention, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier and methods of treatment with the compounds of the invention.

Abstract: Systems and methods for continuous flow polymerase chain reaction (PCR) are provided. The system comprises an injector, a mixer, a coalescer, a droplet generator, a detector, a digital PCR system, and a controller. The injector takes in a sample, partitions the sample into sample aliquots with the help of an immiscible oil phase, dispenses waste, and sends the sample aliquot to the mixer. The mixer mixes the sample aliquot with a PCR master mix and diluting water, dispenses waste, and sends the sample mixture (separated by an immiscible oil) to the coalescer. The coalescer coalesces the sample mixture with primers dispensed from a cassette, dispenses waste, and sends the reaction mixture (separated by an immiscible oil) to the droplet generator. The droplet generator converts the sample mixture into an emulsion where aqueous droplets of the reaction mixture are maintained inside of an immiscible oil phase and dispenses droplets to the digital PCR system.

Abstract: In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I): and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Abstract: The present disclosure is directed to irradiance sensing devices and methods. One such device includes a housing and an optical diffuser coupled to the housing. The housing has an opening that extends into the housing from an outer surface, and the opening has a circular shape at the outer surface of the housing. The optical diffuser has a first region that extends at least partially beyond the outer surface of the housing and a second region housed within the housing. The first region of the optical diffuser has a curved surface, and the optical diffuser includes a cavity extending at least partially into the second region.

Abstract: The invention discloses a synthesizing method of benzimidazole derivant and intermediate, which is characterized by the following: proceeding arylation among aryl halide and primary amine; adopting L-pro as additive, cuprous iodide as catalyst; proceeding molecular arylation coupling reaction for aryl iodide or aryl bromide and primary amine; adopting iodo phenylamine compound and bromophenylamine compound as starting material; synthesizing the material through several-step transformation.

Abstract: Provided herein are systems, methods, and compositions for bioluminescence-triggered catalysis of bioorthogonal labeling chemistries in a proximity dependent manner. In particular, provided herein are bioluminescent proteins or complexes, luminophore substrates thereof, photocatalysts or photosensitizers, activatable labels, and systems thereof, and methods of catalytically activating the activatable labels via bioluminescence-triggered catalysis.

Abstract: Disclosed herein are compounds that can be used to selectively detect nitric oxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting nitric oxide using the compounds.

Abstract: Provided herein are compounds, compositions, systems, and methods for photoactivatable labeling, which can be actuated within biological systems. In particular, compounds disclosed herein include vinyl-extended-aryl azide moieties that undergo photoactivation to generate reactive intermediates, which can form covalent linkages with biomolecules. The photoactivation can be conducted by a variety of mechanisms including ultraviolet (UV) irradiation, visible light irradiation, or energy transfer (e.g., from a photocatalyst). The compounds also include functional moieties that provide useful functionalities, for example detection of biomolecules, such as fluorophores, capture elements (e.g., biotin), or reactive moieties (e.g., click handles) and bifunctional moieties comprising a bioactive compound and a detection/capture element.

Abstract: Disclosed herein are compounds that can be used to selectively detect superoxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting superoxide using the compounds.

Abstract: Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

Abstract: Disclosed herein are compounds that can be used to selectively detect nitric oxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting nitric oxide using the compounds.

Abstract: Disclosed herein are compounds that can be used to selectively detect superoxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting superoxide using the compounds.

Abstract: In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Abstract: Implementations described herein relate to systems and methods to provide platform agnostic query acceleration. In some implementations, a method includes receiving, at a processor associated with a query acceleration service, a request from an client/application, wherein the request conforms to a particular wire protocol of a plurality of supported wire protocols, and wherein the request includes header data and body content data, analyzing the request to identify at least one of a query and a command in the body content data, determining an optimal matched model of the one or more query acceleration models, rewriting the query based on the optimal matched model, transmitting the rewritten query to the query processing platform, receiving a response to the rewritten query or the query from the query processing platform, and transmitting the received response to the application, wherein the transmission is configured based on the particular wire protocol.

Abstract: A pizza cheese composition may include a dairy cheese and analogue cheese. The dairy cheese can provide at least 10 weight percent of the pizza cheese composition. The analogue cheese may include one or more fats, casein protein, guar gum, and one or more hydrocolloid other than guar gum. The fat can range from 15 to 35 weight of the analogue cheese and be obtained from a non-dairy source. The casein protein can be present in an amount less than 3 weight percent of the analogue cheese. The hydrocolloid other than guar gum may range from 10 to 25 weight percent of the analogue cheese. An example specifies that a ratio of a weight of guar gum divided by a weight of casein protein is at least 1.0. This can provide enhanced freeze/thaw stability notwithstanding the reduced levels of casein protein used in the composition.